- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Apr 2, 2024
Product Development
Neurology’s false choice: symptomatic vs. disease-modifying
A new theme in Alzheimer’s is aiming for early symptom relief PLUS long-term disease modification
BioCentury | Dec 14, 2022
Emerging Company Profile
Lucy: mitochondrial solutions to CNS diseases
Company’s first indications are Parkinson’s disease, Rett syndrome
BioCentury | Mar 3, 2021
Deals
March 3 Quick Takes: Resilience acquires two manufacturing facilities in North America; plus Agilent-Resolution, AbbVie-Mitokinin, Fusion-Ipsen, LianBio-ReViral and Lava
National Resilience Inc. acquired two North American biopharma manufacturing facilities: a 310,000-square-foot biologics and advanced therapeutics Boston plant from Sanofi (Euronext:SAN; NASDAQ:SNY)
BioCentury | Jul 26, 2019
Translation in Brief
GI infection as Parkinson’s trigger
McGill, UMontreal team describe chain of events leading from GI infection to Parkinson’s disease
Items per page:
1 - 10 of 16